Qu Biologics Granted Three New Patents for Treating Inflammatory Bowel Disease, Colon Cancer and Skin Cancer

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 17, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today that it has recently been granted three new patents.

New Zealand Patent 606490 issued on July 28, 2015, covering treatments for inflammatory bowel diseases with a wide range of microbial SSI formulations.

Japanese Patent 5783915 issued on July 31, 2015, covering the treatment of colon cancers using formulations derived from E. coli, such as Qu Biologics' QBECO SSI. Qu Biologics' QBECO, an investigational treatment currently being studied in clinical trials for Crohn's disease and ulcerative colitis, is derived from components of inactivated E. coli and is designed to restore normal immune function in the gastrointestinal tract.

Japanese Patent 5784103 also issued on July 31, 2015, covering the treatment of skin cancers using formulations derived from S. aureus, such as Qu Biologics' QBSAU SSI. Qu Biologics' QBSAU is derived from components of inactivated S. aureus and is designed to stimulate an immune response to treat melanoma, breast and bone cancers.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSIs), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases. The company is currently conducting clinical trials in Crohn's disease, ulcerative colitis and non-small cell lung cancer to study SSI treatment.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.quibd.com.